Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

IMDX vs CSTL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CSTL Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–2 Matrix Metrics)

CSTL Overall Winner 6-Pillar Tally: IMDX 1 – 5 CSTL Matrix Metrics: IMDX 2 – 6 CSTL

As of Nov 19, 2026, Castle Biosciences, Inc. (CSTL) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas CSTL carries 62.4/100 (BUY) at $33.41 (N/M Forward P/E, -7.4% operating margin).

  • Growth vs. Quality Trade-Off: CSTL earns the overall head-to-head edge with a stronger Unified Composite Score (62.4/100 BUY vs. IMDX 45.5/100 HOLD) and 1.12β · 53% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile CSTL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMDX vs CSTL
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10
CSTL NASDAQ Head-to-Head Winner
Castle Biosciences, Inc. Common Stock
Services-Medical Laboratories
$33.41
+0.07% 1D
Market Cap $1.0B
TTM Revenue $377M
Forward P/E N/M
Beta / 30D Vol 1.12β · 53% Vol
Unified Composite Score
62.4 / 100 BUY
Tech 71.0 Fund 57.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $34.47 · SMA50: $34.39

6-Pillar Scorecard Institutional Category Breakdown (IMDX 1 – 5 CSTL)

Columns: Metric · IMDX · CSTL
1. Valuation Multiples CSTL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.8x 2.7x
2. Growth & Scale IMDX
Revenue Growth (YoY) +115.0% +23.9%
Earnings Growth (YoY) +0.0% -51.6%
TTM Revenue (USD) $2.0M $377M
Market Cap $52.1M $1.0B
3. Profitability & Quality CSTL
Gross Margin 55.6% 77.1%
Operating Margin -1883.2% -7.4%
Net Profit Margin 0.0% -6.1%
Return on Equity (ROE) -23603.1% -4.9%
4. Balance Sheet & Cash Flow CSTL
Cash Generation (TTM) -$31M -$12M EBITDA
Cash Flow Margin N/A -3.2% EBITDA Mgn
Net Cash / Leverage $15M Net Cash $15.55 Book/Sh · -4.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CSTL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 99.4% (12th %ile) 41.4% (<1st %ile)
Put/Call OI Skew 0.08x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CSTL
OpEx & R&D Intensity N/A 84.5% of Rev ($319M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMDX (2) vs CSTL (6)
Institutional Metric IMDX CSTL Criterion Row Edge
Market Capitalization
Scale
$52.1M $1.0B Larger Scale CSTL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+115.0% +23.9% Higher Growth IMDX
Operating Margin (TTM)
Profitability
-1883.2% -7.4% Higher Margin CSTL
Net Profit Margin
Profitability
0.0% -6.1% Higher Margin IMDX
Return on Equity (ROE)
Capital Efficiency
-23603.1% -4.9% Higher ROE CSTL
52-Week Range Position
Momentum
3% ($2–$8) 59% ($18–$44) Stronger Trend CSTL
Beta / 30D Volatility
Risk Regime
2.91β · 76% Vol 1.12β · 53% Vol Lower Realized Risk CSTL
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 62.4 / 100 (BUY) Higher Composite CSTL
Trailing 12M Revenue (USD)
Operating Scale
$2.0M $377M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
55.6% 77.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.8x EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($15M Net Cash) -$12M EBITDA ($15.55 Book/Sh · -4.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CSTL +42.22 pp
IMDX: -45.03% · CSTL: -2.81%
3M Horizon CSTL +59.43 pp
IMDX: -61.75% · CSTL: -2.32%
6M Horizon CSTL +134.4 pp
IMDX: -71.77% · CSTL: +62.63%
1Y Horizon CSTL +73.35 pp
IMDX: -73.78% · CSTL: -0.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMDX vs CSTL. Trailing 12-month operating profitability (IMDX -1883.2% vs CSTL -7.4%) and valuation multiples (IMDX N/M vs CSTL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMDX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross Margin55.6%
Op. Margin-1883.2%
ROE / Fwd P/E-23603.1% · N/M
CSTL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$377M
Gross Margin77.1%
Op. Margin-7.4%
ROE / Fwd P/E-4.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CSTL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CSTL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CSTL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.0B market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 84.5% of Rev ($319M)
90D Engineering Disclosures 0 Published

Investor FAQ IMDX vs CSTL Key Questions & Quantitative Answers

As of Nov 19, 2026, Castle Biosciences, Inc. (CSTL) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas CSTL carries 62.4/100 (BUY) at $33.41 (N/M Forward P/E, -7.4% operating margin). Growth vs. Quality Trade-Off: CSTL earns the overall head-to-head edge with a stronger Unified Composite Score (62.4/100 BUY vs. IMDX 45.5/100 HOLD) and 1.12β · 53% Vol risk profile, whereas IMDX leads top-line expansion (+115.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile CSTL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMDX leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with CSTL at +23.9% YoY revenue growth and -51.6% YoY earnings growth on $377M TTM revenue (77.1% gross margin, -7.4% operating margin). On trailing 12-month operating scale, IMDX generates $2.0M in USD-normalized revenue versus $377M for CSTL. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus 84.5% of Rev ($319M) (0 disclosures) for CSTL.

CSTL screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas CSTL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-3.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus CSTL (-4.9% ROE) capital efficiency.

In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, CSTL carries 41.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.